Close Menu

NEW YORK (GenomeWeb) – Newly public Co-Diagnostics reported today revenues of $7,662 in 2017 versus no revenues in the prior year.

For the 12-month period ended Dec. 31, Co-Diagnostics' net loss swelled to $7 million, or $.63 per share, from $1.9 million, or $.20 per share, in 2016.

R&D costs climbed to $1 million from $731,474, while SG&A expenses rose to $3.5 million from $919,001.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.